Open AccessIs excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?
Author(s) -
Asude Aksoy,
Emin Tamer Elkıran,
Hakan Harputluoğlu,
Adile Ferda Dağlı,
Abdurrahman Işıkdoğan,
Zuhat Urakçı
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.206865
Subject(s) - ercc1 , immunohistochemistry , medicine , nasopharyngeal carcinoma , stage (stratigraphy) , oncology , p53 expression , biopsy , biomarker , chemotherapy , carcinoma , pathology , gene , radiation therapy , biology , nucleotide excision repair , dna repair , paleontology , biochemistry
To determine the prognostic value of excision repairs cross-complementation group1 (ERCC1) gene in cases with nasopharyngeal carcinoma (NPC) treated with platinum-containing chemotherapy (PCT).